Inferior Vena Cava Filters

Inferior vena cava (IVC) filters are intravascular devices used to reduce the risk of pulmonary embolism by capturing thrombi traveling from the lower extremities when anticoagulation is contraindicated, ineffective, or insufficient. Clinical use is shaped by venous thromboembolism risk, trauma and surgical pathways, patient bleeding risk, device retrievability, and the need for structured follow-up and removal when protection is no longer required.

The landscape has shifted from broad prophylactic placement toward more selective, indication-based use. Contemporary practice places greater emphasis on documented contraindications to anticoagulation, multidisciplinary risk assessment, informed consent, retrieval planning, and surveillance for complications. Retrievable devices have increased procedural flexibility, but they also require reliable tracking because prolonged dwell time can raise the difficulty of removal and the risk of device-related complications. Guideline interpretation and regulatory scrutiny continue to reinforce careful patient selection and post-placement management.

Artificial intelligence can support IVC-filter care by identifying eligible patients in electronic records, extracting bleeding and thromboembolic risk factors, flagging overdue retrievals, and prioritizing imaging or specialist review. Natural-language processing may help detect documented indications and contraindications that are difficult to capture in structured fields. These tools should remain decision-support systems: clinical validation, transparent performance monitoring, privacy safeguards, and clinician oversight are essential because incomplete records, biased training data, and false alerts can affect patient safety.

In North America, mature interventional and trauma-care infrastructure supports selective placement and retrieval programs, while care coordination remains important for patients moving between hospitals. Europe generally emphasizes guideline-led selection, device surveillance, and coordinated follow-up, with implementation varying across health systems. Asia-Pacific combines advanced tertiary-care capacity in several markets with uneven access and follow-up infrastructure across the wider region. Latin America faces differences in specialist availability, procurement, and continuity of care. In the Middle East, concentrated advanced-care capacity coexists with varied referral pathways. Africa’s needs are strongly influenced by access to imaging, anticoagulation management, interventional expertise, and reliable longitudinal follow-up.

ASEAN markets show substantial variation in specialist capacity, hospital infrastructure, regulatory processes, and post-procedure tracking. BRICS countries span large and diverse patient populations, with differing access to trauma services, vascular expertise, imaging, and device procurement. The European Union benefits from shared clinical and regulatory dialogue, although national reimbursement and service organization differ. G7 health systems generally have stronger interventional capacity and data infrastructure, but still face challenges in coordinating retrieval across fragmented care settings. GCC countries often have concentrated tertiary-care capabilities and cross-border referral patterns. NATO members vary widely in health-system organization, yet trauma readiness and interoperability can influence clinical pathways in selected settings.

Australia combines advanced procedural services with a focus on coordinated follow-up across large geographic areas. Brazil’s practice is shaped by regional differences in specialist access and public–private care organization. Canada must account for dispersed populations and interprovincial continuity of care. China is expanding sophisticated hospital capacity while implementation remains heterogeneous across regions. France, Germany, Italy, and Spain operate within European clinical and regulatory frameworks but differ in referral, reimbursement, and retrieval organization. India has high-volume tertiary centers alongside uneven access to advanced intervention. Japan and South Korea have technically capable hospital systems with distinct reimbursement and clinical governance structures. Mexico faces differences in access between major urban centers and other areas. Russia’s care availability and referral pathways vary across its expansive geography. The United Kingdom emphasizes guideline-based pathways and service coordination. The United States has extensive interventional capacity, while fragmented follow-up can complicate retrieval.

Leaders should prioritize validated indications, standardized consent, and a documented retrieval plan before placement whenever clinically appropriate. Establishing a registry or automated tracking workflow can link the device, indication, responsible clinician, target review date, imaging status, and retrieval outcome. Organizations should audit placement appropriateness, retrieval completion, complications, and loss to follow-up by patient subgroup and care setting. Training should reinforce multidisciplinary decision-making, while procurement should assess retrievability, imaging compatibility, procedural support, and total care requirements rather than device attributes alone. AI initiatives should begin with narrowly defined workflow problems, prospective validation, human review, and measurable safety outcomes.

This executive summary uses a structured qualitative synthesis of established clinical guidance, regulatory communications, peer-reviewed evidence, device-safety literature, health-system publications, and publicly documented regional care patterns. Findings were organized around indications, contraindications, retrieval practice, complications, access, governance, and digital decision support. Regional, group, and country observations are presented as contextual comparisons rather than quantitative rankings. Because practices and recommendations evolve, local clinical guidelines, regulatory requirements, and institutional protocols should be checked before operational decisions are made.

IVC filters remain an important option for carefully selected patients at risk of pulmonary embolism when standard anticoagulation strategies cannot provide adequate protection. The central opportunity is not indiscriminate expansion, but safer, more coordinated care: clear indications, appropriate device selection, reliable follow-up, and retrieval when clinically suitable. Health systems that combine multidisciplinary governance with robust tracking and responsibly validated digital tools can improve consistency while reducing avoidable long-term device-related risk.